Calithera Biosciences Incorporated (NASDAQ:CALA) Shorted Shares Increased By 0.03%

September 17, 2017 - By Peter Erickson

 Calithera Biosciences Incorporated (NASDAQ:CALA) Shorted Shares Increased By 0.03%

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.44, from 0.76 in 2016Q3. It increased, as 9 investors sold Calithera Biosciences Inc shares while 6 reduced holdings. 4 funds opened positions while 14 raised stakes. 5.98 million shares or 0.90% more from 5.92 million shares in 2016Q3 were reported.
Tfs Cap Limited Co invested in 28,408 shares or 0.02% of the stock. The Massachusetts-based Geode Capital Ltd Limited Liability Company has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Connor Clark Lunn Inv Mgmt Limited invested in 0% or 10,200 shares. First Eagle Investment Mgmt Lc holds 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA) for 438,103 shares. Ontario – Canada-based Manufacturers Life Insur Com The has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Jacobs Levy Equity has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). 17,457 are owned by Northern. Blackrock Institutional Tru Na reported 260,883 shares stake. Adage Cap Prns Gru Lc holds 0.03% or 3.64M shares in its portfolio. Goldman Sachs Group invested in 16,149 shares or 0% of the stock. Oxford Asset Mgmt has 0.01% invested in Calithera Biosciences Inc (NASDAQ:CALA). 2,467 are held by Blackrock Inv Mgmt Ltd Limited Liability Company. Rbf Lc accumulated 0.01% or 13,000 shares. Howland Capital Ltd Limited Liability Company invested in 0% or 12,000 shares. State Bank Of Ny Mellon holds 0% or 27,825 shares.

The stock of Calithera Biosciences Incorporated (NASDAQ:CALA) registered an increase of 0.03% in short interest. CALA’s total short interest was 2.92M shares in September as published by FINRA. Its up 0.03% from 2.92M shares, reported previously. With 386,200 shares average volume, it will take short sellers 8 days to cover their CALA’s short positions. The short interest to Calithera Biosciences Incorporated’s float is 22.25%.

The stock decreased 0.66% or $0.1 on September 15, reaching $15.05. About 1.01M shares traded or 114.09% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has risen 278.82% since September 17, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $533.92 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage

Among 4 analysts covering Calithera Biosciences (NASDAQ:CALA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Calithera Biosciences had 8 analyst reports since July 24, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 12 report. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. Citigroup initiated the shares of CALA in report on Tuesday, October 25 with “Sell” rating. The firm has “Buy” rating given on Tuesday, March 28 by H.C. Wainwright. Citigroup initiated the stock with “Buy” rating in Friday, July 24 report. The rating was upgraded by Citigroup to “Neutral” on Tuesday, January 24. On Thursday, January 5 the stock rating was initiated by H.C. Wainwright with “Buy”.

More notable recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: which released: “Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care …” on March 01, 2017, also with their article: “Here’s Why Calithera Biosciences Stock Gained as Much as 16.4% Today” published on May 10, 2017, published: “Calithera Biosciences to Participate in the Citi 12th Annual Biotech …” on August 30, 2017. More interesting news about Calithera Biosciences Inc (NASDAQ:CALA) were released by: and their article: “Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy?” published on September 08, 2017 as well as‘s news article titled: “Incyte and Calithera Biosciences Announce Global Collaboration to Develop and …” with publication date: January 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.